



Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases

Guest Editor:

**Prof. Dr. Kutty Selva
Nandakumar**

Department of Environmental
and Biosciences, School of
Business, Innovation and
Sustainability (FIH), Halmstad
University, Halmstad, Sweden

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Vaccines are essential in eradicating or controlling many infectious diseases. In this context, several possible mechanisms (epitope spreading, bystander activation molecular mimicry, etc.) are postulated. In addition, microbial components are indispensable in several animal models of autoimmune diseases. Recent concerns in this area include the autoimmune manifestations associated with COVID-19 vaccines, although incidences of autoimmune diseases after other vaccinations were reported as well. At the same time, people living with autoimmune disease(s) need to take care of themselves to protect against various infections. Therefore, on this topic, we invite original and review articles covering the following three aspects: 1. Central theme: development of vaccines for infectious diseases or autoimmune diseases; 2. Exploration: how vaccines for infectious diseases might cause autoimmune diseases; 3. Accessories: vaccine adjuvants (natural and synthetic polymers, microbial and nonmicrobial components, their mode of action, and beneficial and adverse effects).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com